Straits Times Index
3,065.94 -20.48 (-0.66%) S&P 500
4,542.84 -7.59 (-0.17%) Dow
35,328.36 -5.11 (-0.01%) Nasdaq
14,215.75 -25.27 (-0.18%) Bitcoin USD
37,450.79 +599.82 (+1.63%) CMC Crypto 200
775.76 +11.07 (+1.45%)
Carmila S.A. (CARM.PA)
- Business Wire
Carmila: Termination of Liquidity Contract With BNP Paribas Arbitrage and New Liquidity Contract With Kepler Cheuvreux
PARIS, November 10, 2023--Regulatory News: On 10 November 2023, the liquidity contract between BNP Paribas Arbitrage and Carmila (Paris:CARM) dated 28 June 2019 was terminated. On 3 November 2023, Carmila and Kepler Cheuvreux signed a liquidity contract concerning the liquidity of Carmila shares (ISIN : FR0010828137), (the Shares) admitted for trading on Euronext Paris (the Contract), which will begin on 13 November 2023.
- Business Wire
CARMILA: Information Concerning the Total Number of Voting Rights and Share
PARIS, November 09, 2023--Regulatory News: CARMILA (Paris:CARM):
- PR Newswire
Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2023, and highlighted recent business updates.
